Shenzhen Edge Medical (2675) H2 2025 earnings summary

Executive summary

• Revenue surged 184.8% year-over-year to RMB455.7 million, driven by rapid growth in domestic and overseas sales of surgical robots.

• Net loss narrowed by 59.4% to RMB88.6 million, reflecting strong sales and improved cost management.

• Gross profit margin rose to 66.0% from 61.3% year-over-year, highlighting operational efficiency.

• Major product milestones included regulatory approvals in China and the EU for multi-port and single-port surgical robots, and the launch of a bronchoscope robot.

• Over 14,000 robot-assisted clinical procedures completed, with significant adoption in top-tier hospitals in China and abroad.

Financial highlights

• Revenue: RMB455.7 million (up 184.8% YoY); gross profit: RMB300.7 million (up 206.5% YoY).

• Net loss: RMB88.6 million (down 59.4% YoY); adjusted net loss (non-IFRS): RMB20.5 million (down 88.5% YoY).

• R&D expenses: RMB185.2 million (down 18.1% YoY); selling and marketing expenses: RMB134.8 million (up 33.2% YoY).

• Cash and cash equivalents: RMB86.0 million; financial assets at FVPL: RMB727.8 million.

• No dividends declared for the year.

Outlook and guidance

• Plans to expand product portfolio, deepen domestic market penetration, and accelerate global expansion, especially in Europe, Middle East, Asia-Pacific, Africa, and Latin America.

• Focus on building a global telesurgery ecosystem and further R&D investment for next-generation intelligent robotic surgery platforms.

• Management confident in sustaining growth through innovation, commercialization, and internationalization.